Crisaborole

• Description:

  Crisaborole (AN-2728) is a potent inhibitor of PDE4 and cytokine release; inhibit PDE4 with an IC50 of 0.49 μM.

• Product Name Alternative:

  AN-2728; PF-06930164

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  Phosphodiesterase (PDE)

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology; Cancer

• Assay Protocol:

  https://www.medchemexpress.com/AN-2728.html

• Purity:

  99.97

• Solubility:

  DMSO : ≥ 100 mg/mL

• Smiles:

  N#CC1=CC=C(OC2=CC=C(B(O)OC3)C3=C2)C=C1

• Molecular Formula:

  C14H10BNO3

• Molecular Weight:

  251.05

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Akama T, et al. Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis. Bioorg Med Chem Lett. 2009 Apr 15;19 (8) :2129-32.|[2]Nazarian R, et al. AN-2728, a PDE4 inhibitor for the potential topical treatment of psoriasis and atopic dermatitis. Curr Opin Investig Drugs. 2009 Nov;10 (11) :1236-42.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  Store at room temperature, keep dry and cool

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• Isoform:

  PDE4

• CAS Number:

  [906673-24-3]